3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients

  • B. Bondy
  • F. X. Dengler
  • W. H. Oertel
  • M. Ackenheil
Part of the Key Topics in Brain Research book series (KEYTOPICS)


The binding parameters (Bmax and KD) for the dopamine antagonist 3H-spiperone were investigated in psychiatric patients and in patients with Parkinsonian diesease. Bmax values were found to be increased in acute, unmedicated schizophrenics (n = 46), during neuroleptic treatment (n = 25) and in chronic schizophrenics (n = 6) being under long term neuroleptic treatment. In all other psychiatric patients, including endogenous depressives, manics, neurotics, borderline and alcoholic patients the binding capacity did not differ from that of healthy control persons (n = 50). This finding suggests, that increased 3H-spiperone binding could be valid as marker for schizophrenia.. In contrast to that, 3H-spiperone binding was found to be decreased in drug free (n = 5) and in MAO-B (n = 2) or short term L-DOPA (n = 3) treated Parkinsonian patients (mean decrease 80%) as compared to age and sex matched controls. The significance of the later finding has to be further investigated.


Schizophrenic Patient Psychiatric Patient Parkinsonian Patient Neuroleptic Treatment Chronic Schizophrenic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Biziere K, Guillaumin JM, Degenne D, Bardos P, Renoux M, Renoux G (1985) Lateralized neocortical modulation of the T-cell lineage. In: Guillemin R (ed) Neural modulation of immunity. Raven Press, New York, pp 81–93Google Scholar
  2. Bondy B, Ackenheil M, Elbers R, Fröhler M (1985) Binding of 3H-spiperone to lymphocytes: a biological marker in schizophrenia? Psychiat Res 15: 41–48CrossRefGoogle Scholar
  3. Bondy B, Ackenheil M (1987) 3H-spiperone binding sites in lymphocytes as possible vulnerability marker in schizophrenia. J Psychiat Res 21: 521–529PubMedCrossRefGoogle Scholar
  4. Chang WH, Scheinin M, Burns RS, Linnoila M (1983) Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection. Acta Pharmacol Toxicol 53: 275–279CrossRefGoogle Scholar
  5. Cramer H, Warter JM, Renaud B (1984) Analysis of neurotransmitter metabolites and adenosine 3’, 5’-monophosphate in the CSF of patients with extrapyramisal motor disorders. In: Hassler RG, Christ JF (eds) Advances in neurology, vol 40. Raven Press, New York, pp 431–435Google Scholar
  6. Guttman M, Seeman P (1986) Dopamine D 2 receptor density in parkinsonian brain is constant for duration of disease, age and duration of L-DOPA therapy. Adv Neurol 45: 51–57Google Scholar
  7. Fleminger S, Jenner P, Marsden CD (1982) Are dopamine receptors present on human lymphocytes? J Pharm Pharmacol 34: 658–663PubMedCrossRefGoogle Scholar
  8. LeFur G, Zarifian E, Phan T, Couche H, Flamier A, Bouchami F, Burgevin MC, Loo H, Gerard A, Uzan A (1980) Identification of stereospecific 3H-spiroperidol binding sites in mammalian lymphocytes. Life Sci 26: 1139–1148CrossRefGoogle Scholar
  9. LeFur G, Meininger VA, Baulac M, Uzan A (1981) Recepteurs dopaminergiques lymphocytaires et maladie de parkinson idiopathique. Rev Neurol 137: 89–96Google Scholar
  10. LeFur G, Zarifian E, Phan T, Couche H, Flamier A, Bouchami F, Burgevin MC, Loo H, Gerard A, Uzan A (1983) 3H-spiperone binding in lymphocytes: changes in two different groups of schizophrenics and effect of neuroleptic treatment. Life Sci 32: 249–254CrossRefGoogle Scholar
  11. Maloteaux JM, Gossuin W, Waterkyn C, Laduron PM (1983) Trapping of labelled ligand in intact cells: pitfalls in binding studies. Biochem Pharmac 23: 2543–2548CrossRefGoogle Scholar
  12. Ovadia H, Lubetzky-Korn I, Abramsky O (1987) Dopamine receptors on isolated membranes of rat thymocytes. Ann NY Acad Sci 496: 211–216PubMedCrossRefGoogle Scholar
  13. Rotstein E, Ram RK, Singal DP, Barone D (1983) Lymphocyte 3H-spiroperidol binding in schizophrenia: preliminary findings. Progr Neuro-Psychopharmac Biol Psychiat 7: 720–723Google Scholar
  14. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152PubMedCrossRefGoogle Scholar
  15. Shaskan EG, Ballow M, Oreland L, Wadell G (1983) Is there a functional significance for dopamine antagonist binding on lymphoid cells? Biol Psychiat 12: 123–145Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • B. Bondy
    • 1
  • F. X. Dengler
    • 1
  • W. H. Oertel
    • 2
  • M. Ackenheil
    • 1
  1. 1.Psychiatric Clinic of University MunichFederal Republic of Germany
  2. 2.Neurological Clinic of University MunichFederal Republic of Germany

Personalised recommendations